

NCT ID	NCT03795311
Title	Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
Phase	Phase 1, Phase 2
Date Added	2019-01-07
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	FOLFIRINOX Bevacizumab
Tags	MSS/ MMRp
NCT ID	NCT03785249
Title	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Phase	Phase 1
Date Added	2018-12-24
Location	Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	afatinib, cetuximab, MRTX849, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03783403

Title	A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers
Phase	Phase 1
Date Added	2018-12-21
Location	Alabama, United States Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	CC-95251, cetuximab, Rituximab
Tags	MSS/ MMRp
NCT ID	NCT03772561
Title	Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase	Phase 1
Date Added	2018-12-11
Location	Singapore
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	AZD5363+Olaparib+Durvalumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03745326
Title	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Phase	Phase 1, Phase 2
Date Added	2018-11-19
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03740256
Title	Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase	Phase 1

Date Added	2018-11-14
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	CAdVEC
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03727763
Title	Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Phase	Phase 2
Date Added	2018-11-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	cetuximab, Vemurafenib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03711058
Title	Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2018-10-18
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Copanlisib, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT03692429
Title	alloSHRINK – Standard chemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Phase	Phase 1
Date Added	2018-10-02
Location	Florida, United States Belgium
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	CYAD-101, FOLFIRI, FOLFOX
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03673787
Title	A Trial of Ipatasertib in Combination With Atezolizumab
Phase	Phase 1
Date Added	2018-09-17
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	No

Status	Recruiting
Drugs	Atezolizumab, Ipatasertib
Tags	MSI-H/ MMRd, MSS/ MMRp